Previous 10 | Next 10 |
2023-05-15 16:19:01 ET Celcuity press release ( NASDAQ: CELC ): Q1 GAAP EPS of -$0.55 misses by $0.03 . At March 31, 2023, Celcuity had cash, cash equivalents and short-term investments of $157.5 million. For further details see: Celcuity GAAP EPS of -$0.55 m...
Presented updated results for treatment-naïve patients from Phase 1b study of gedatolisib at the ESMO Breast Cancer Annual Congress - median progression free survival (PFS) was 48.6 months Presented nonclinical prostate cancer data at ASCO GU Cancers Symposium demonstrating the superior...
2023-05-12 07:30:07 ET Celcuity ( NASDAQ: CELC ) reported updated data from a phase 1b trial of gedatolisib in combination with Pfizer's ( PFE ) Ibrance (palbociclib) and Novartis' ( NVS ) Femara (letrozole) to treat patients with breast cancer at the 2023 Eur...
Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozole Median duration of response (DOR) was 46.9 months MINNEAPOLIS, MN / ACCESSWIRE / M...
MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2023 after the stock market close on Monday...
MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting updated results for treatment-naïve patients from the Phase 1b stu...
Gedatolisib demonstrated superior anti-proliferative potency and efficacy in endometrial, ovarian and cervical cancer cell lines compared to other PAM inhibitors evaluated regardless of PTEN, P13K, or AKT mutational status MINNEAPOLIS, MN / ACCESSWIRE / April 18, 2023 / Celcuity Inc. (Nasd...
MINNEAPOLIS, MN / ACCESSWIRE / April 12, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation in the 22nd Annual Needham Virtual Healthcare Conference. Brian Sullivan, Chairman, ...
2023-03-23 20:04:06 ET Celcuity Inc. (CELC) Q4 2022 Earnings Conference Call March 23, 2023, 04:30 PM ET Company Participants Robert Uhl - ICR Westwicke, IR Brian Sullivan - CEO and Co-Founder Vicky Hahne - CFO Igor Gorbatchevsky - Chief Medical Officer ...
2023-03-23 16:02:57 ET Celcuity press release ( NASDAQ: CELC ): Q4 GAAP EPS of -$0.69 misses by $0.25 . At December 31, 2022, Celcuity had cash, cash equivalents and short-term investments of $168.6 million. For further details see: Celcuity GAAP EPS of -$0.6...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. ...
2024-05-30 16:00:09 ET Bradley Canino from Stifel Nicolaus issued a price target of $40.00 for CELC on 2024-05-30 14:29:00. The adjusted price target was set to $40.00. At the time of the announcement, CELC was trading at $15.28. The overall price target consensus is at ...